SCHEMBL5455778

SCHEMBL5455778

NC(=O)c1c(NC(=O)Nc2ccc(F)cc2F)sc2c1CCOC2

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CFTR P13569 1/20 0.55
ANO1 Q5XXA6 5/20 0.50
NPC1 O15118 3/20 0.46
RAB9A P51151 3/20 0.46
CXCR2 P25025 1/20 0.46
PTPRC P08575 1/20 0.45
PTPN2 P17706 1/20 0.45
PTPN1 P18031 1/20 0.45
PTPRB P23467 1/20 0.45
PTPRE P23469 1/20 0.45
MAPT P10636 2/20 0.44
LMNA P02545 1/20 0.44
TP53 P04637 1/20 0.44
MEN1 O00255 1/20 0.44
ALDH1A1 P00352 1/20 0.44
GAA P10253 1/20 0.44
KMT2A Q03164 1/20 0.44
KCNH2 Q12809 2/20 0.43
CNR1 P21554 2/20 0.42
CNR2 P34972 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5451275 0.90 CFTR (0.53) CFTRANO1NPC1RAB9APTPRC
SCHEMBL5447455 0.88 CFTR (0.58) CFTRANO1NPC1RAB9ACXCR2
SCHEMBL5461043 0.88 CFTR (0.57) CFTRANO1NPC1RAB9ACXCR2
SCHEMBL5448456 0.85 NPC1 (0.60) NPC1RAB9AMAPTLMNATP53
SCHEMBL5457888 0.85 ANO1 (0.64) CFTRANO1NPC1RAB9ACXCR2
SCHEMBL5454365 0.84 CFTR (0.55) CFTRANO1NPC1RAB9ACXCR2
SCHEMBL5450806 0.83 CFTR (0.57) CFTRANO1NPC1RAB9ACXCR2
SCHEMBL5460302 0.82 RAB9A (0.47) NPC1RAB9APTPN1MAPTLMNA
SCHEMBL5467558 0.82 RAB9A (0.47) NPC1RAB9APTPN1MAPTLMNA
SCHEMBL5460025 0.82 CFTR (0.55) CFTRANO1NPC1RAB9APTPRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US claimed
EP-1670804-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC Biotech AG (DE) 2006-06-21 EP claimed
WO-2005023818-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC BIOTECH AG (DE) 2005-03-17 WO claimed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents TBCA, PARK7, NFATC1 CFTR 2030/4885ANO1 3245/4885NPC1 2627/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.